SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?


To: Biomaven who wrote (4030)6/6/2001 11:38:07 AM
From: IRWIN JAMES FRANKEL  Read Replies (1) | Respond to of 52153
 
KOSP - What if department???

I agree with rkrw about using Niaspan with a newer and better statin. The downside is multiple drug compliance issues.

So what if BMY sees the market and decides to try and hang on the relationship, market the mevacor/niaspan product while getting the studies done to combine Pravachol with Niaspan.

Is that something that they could get approval for?

ij